AV 0328

Drug Profile

AV 0328

Alternative Names: AV0328

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alopexx Vaccine
  • Class Antibacterials; Oligosaccharides; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bacterial infections
  • Preclinical Staphylococcal infections

Most Recent Events

  • 25 Oct 2017 Immunogenicity and antimicrobial data from the phase I/II trial in Healthy volunteers released by Alopexx Vaccine
  • 25 Oct 2017 Alopexx Vaccine completes a phase I/II trial in Bacterial infections (In volunteers) in USA (IM) (NCT02853617)
  • 25 Oct 2017 Alopexx Vaccine plans a phase II trial for Bacterial infections in first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top